Loading…
Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project
To evaluate outcomes and predictive factors of visual acuity (VA) change after cataract surgery in patients being treated for neovascular age-related macular degeneration (nAMD). Retrospective, matched case-control study. We studied eyes undergoing cataract surgery that had been tracked since they f...
Saved in:
| Published in: | American journal of ophthalmology 2018-06, Vol.190, p.50-57 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c458t-18064e06a2b26a252e5b4ee3deeadbec8d30ee238b1749bbed91d0f37257ffc33 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c458t-18064e06a2b26a252e5b4ee3deeadbec8d30ee238b1749bbed91d0f37257ffc33 |
| container_end_page | 57 |
| container_issue | |
| container_start_page | 50 |
| container_title | American journal of ophthalmology |
| container_volume | 190 |
| creator | Daien, Vincent Nguyen, Vuong Morlet, Nigel Arnold, Jennifer J. Essex, Rohan W. Young, Stephanie Hunyor, Alex Gillies, Mark C. Barthelmes, Daniel Squirrel, D. Field, A. Dayajeewa, C. Essex, R. Dunlop, A. Young, S. Guymer, R. Chow, L. Amini, A. Windle, P. Gillies, M. Chen, J. Perks, M. Saha, N. Phillips, R. Lake, S. Lal, S. Arnold, J. Fraser-Bell, S. Barnes, R. Swamy, B. Barthelmes, D. Day, J.O' Cohn, A. |
| description | To evaluate outcomes and predictive factors of visual acuity (VA) change after cataract surgery in patients being treated for neovascular age-related macular degeneration (nAMD).
Retrospective, matched case-control study.
We studied eyes undergoing cataract surgery that had been tracked since they first started treatment for nAMD. These eyes were compared with a cohort of unoperated phakic eyes being treated for nAMD (3 per case) matched for treatment duration before cataract surgery, baseline VA, age, and length of follow-up.
We included 124 patients that had cataract surgery and 372 matched controls. The mean (95% confidence interval) VA gained was 10.6 letters (7.8, 13.2; P |
| doi_str_mv | 10.1016/j.ajo.2018.03.012 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02335585v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002939418301107</els_id><sourcerecordid>2015411289</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-18064e06a2b26a252e5b4ee3deeadbec8d30ee238b1749bbed91d0f37257ffc33</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEotPCA7BBRmzKIsE_ceKI1TBQijTQCopYWo59M-MoExfbGamvwtPiKKULFmxs-eo7x_fek2UvCC4IJtXbvlC9KygmosCswIQ-ylZE1E1OREMeZyuMMc0b1pQn2WkIfXpWdVk_zU5ow3lSVavs99UUtTtAQGo06NqDsTraI6ALpaPzAa27CB5tVFQ-VdD3ye_A3yE7omsVLYwxoJ827tFXcEcV9DQoj9Y7yD0MKoJBX9RS-wA7GMEnjRsLdLNPP9jdPqJvEO2oBvR-sKMZIYRXqQvXg47PsiedGgI8v7_Psh8XH282l_n26tPnzXqb65KLmGbFVQm4UrSl6eAUeFsCMAOgTAtaGIYBKBMtqcumbcE0xOCO1ZTXXacZO8veLL57Nchbbw_K30mnrLxcb-Vcw5QxzgU_ksSeL-ytd78mCFEebNAwDGoENwWZsuAlIVQ0CX39D9q7yadRZ6qkRFDSzBRZKO1dCB66hw4IlnPIspcp5NlYSMxkCjlpXt47T-0BzIPib6oJeLcAkNZ2tOBl0CkqncL1abHSOPsf-z-Db7gg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2042182199</pqid></control><display><type>article</type><title>Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project</title><source>ScienceDirect Journals</source><creator>Daien, Vincent ; Nguyen, Vuong ; Morlet, Nigel ; Arnold, Jennifer J. ; Essex, Rohan W. ; Young, Stephanie ; Hunyor, Alex ; Gillies, Mark C. ; Barthelmes, Daniel ; Squirrel, D. ; Field, A. ; Dayajeewa, C. ; Essex, R. ; Dunlop, A. ; Young, S. ; Guymer, R. ; Chow, L. ; Amini, A. ; Windle, P. ; Gillies, M. ; Chen, J. ; Perks, M. ; Saha, N. ; Phillips, R. ; Lake, S. ; Lal, S. ; Arnold, J. ; Fraser-Bell, S. ; Barnes, R. ; Swamy, B. ; Barthelmes, D. ; Day, J.O' ; Cohn, A.</creator><creatorcontrib>Daien, Vincent ; Nguyen, Vuong ; Morlet, Nigel ; Arnold, Jennifer J. ; Essex, Rohan W. ; Young, Stephanie ; Hunyor, Alex ; Gillies, Mark C. ; Barthelmes, Daniel ; Squirrel, D. ; Field, A. ; Dayajeewa, C. ; Essex, R. ; Dunlop, A. ; Young, S. ; Guymer, R. ; Chow, L. ; Amini, A. ; Windle, P. ; Gillies, M. ; Chen, J. ; Perks, M. ; Saha, N. ; Phillips, R. ; Lake, S. ; Lal, S. ; Arnold, J. ; Fraser-Bell, S. ; Barnes, R. ; Swamy, B. ; Barthelmes, D. ; Day, J.O' ; Cohn, A. ; Fight Retinal Blindness! Study Group</creatorcontrib><description>To evaluate outcomes and predictive factors of visual acuity (VA) change after cataract surgery in patients being treated for neovascular age-related macular degeneration (nAMD).
Retrospective, matched case-control study.
We studied eyes undergoing cataract surgery that had been tracked since they first started treatment for nAMD. These eyes were compared with a cohort of unoperated phakic eyes being treated for nAMD (3 per case) matched for treatment duration before cataract surgery, baseline VA, age, and length of follow-up.
We included 124 patients that had cataract surgery and 372 matched controls. The mean (95% confidence interval) VA gained was 10.6 letters (7.8, 13.2; P < .001) 12 months after surgery; 26.0% had gained ≥3 lines and 1.6% had lost ≥3 lines of VA. Visual acuity (mean [standard deviation]) 12 months after surgery was higher in eyes that had cataract extraction compared with controls (65.8 [17.1] vs 61.3 [20.8] letters, respectively, P = .018). The proportion of visits where the choroidal neovascular (CNV) lesion was graded active and the mean number of injections were similar before and after surgery (P = .506 and P = .316, respectively), whereas both decreased in the control group, suggesting that surgery modestly increased the level of activity of the CNV lesion. Mean [SD] VA prior to surgery was lower in eyes that gained ≥15 letters compared with eyes that gained 0-14 letters (40.2 [21.4] vs 62.1 [15.1], P < .001). Patients undergoing cataract surgery within the first 6 months of anti-VEGF therapy were more likely to lose rather than gain vision (20.8% lost vision vs 12.8% and 4.4% gaining ≥15 or 0-14 letters respectively, P = .023). Age, receiving an injection at least 2 weeks before surgery, and the CNV lesion type had no discernible association with VA outcomes.
We found evidence of a modest effect of cataract surgery on CNV lesion activity in eyes being treated for nAMD. Despite this, visual outcomes were reassuringly good. Cataract surgery within 6 months of starting treatment for nAMD should be avoided if possible.</description><identifier>ISSN: 0002-9394</identifier><identifier>EISSN: 1879-1891</identifier><identifier>DOI: 10.1016/j.ajo.2018.03.012</identifier><identifier>PMID: 29550186</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Age ; Aged ; Angiogenesis Inhibitors - therapeutic use ; Case-Control Studies ; Cataract Extraction ; Cataracts ; Choroidal Neovascularization - drug therapy ; Choroidal Neovascularization - physiopathology ; Ethics ; Eye surgery ; Female ; Human health and pathology ; Humans ; Intravitreal Injections ; Life Sciences ; Macular degeneration ; Male ; Ophthalmology ; Pseudophakia - physiopathology ; Retrospective Studies ; Treatment Outcome ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Visual Acuity - physiology ; Wet Macular Degeneration - drug therapy ; Wet Macular Degeneration - physiopathology</subject><ispartof>American journal of ophthalmology, 2018-06, Vol.190, p.50-57</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Jun 2018</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c458t-18064e06a2b26a252e5b4ee3deeadbec8d30ee238b1749bbed91d0f37257ffc33</citedby><cites>FETCH-LOGICAL-c458t-18064e06a2b26a252e5b4ee3deeadbec8d30ee238b1749bbed91d0f37257ffc33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29550186$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.umontpellier.fr/hal-02335585$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Daien, Vincent</creatorcontrib><creatorcontrib>Nguyen, Vuong</creatorcontrib><creatorcontrib>Morlet, Nigel</creatorcontrib><creatorcontrib>Arnold, Jennifer J.</creatorcontrib><creatorcontrib>Essex, Rohan W.</creatorcontrib><creatorcontrib>Young, Stephanie</creatorcontrib><creatorcontrib>Hunyor, Alex</creatorcontrib><creatorcontrib>Gillies, Mark C.</creatorcontrib><creatorcontrib>Barthelmes, Daniel</creatorcontrib><creatorcontrib>Squirrel, D.</creatorcontrib><creatorcontrib>Field, A.</creatorcontrib><creatorcontrib>Dayajeewa, C.</creatorcontrib><creatorcontrib>Essex, R.</creatorcontrib><creatorcontrib>Dunlop, A.</creatorcontrib><creatorcontrib>Young, S.</creatorcontrib><creatorcontrib>Guymer, R.</creatorcontrib><creatorcontrib>Chow, L.</creatorcontrib><creatorcontrib>Amini, A.</creatorcontrib><creatorcontrib>Windle, P.</creatorcontrib><creatorcontrib>Gillies, M.</creatorcontrib><creatorcontrib>Chen, J.</creatorcontrib><creatorcontrib>Perks, M.</creatorcontrib><creatorcontrib>Saha, N.</creatorcontrib><creatorcontrib>Phillips, R.</creatorcontrib><creatorcontrib>Lake, S.</creatorcontrib><creatorcontrib>Lal, S.</creatorcontrib><creatorcontrib>Arnold, J.</creatorcontrib><creatorcontrib>Fraser-Bell, S.</creatorcontrib><creatorcontrib>Barnes, R.</creatorcontrib><creatorcontrib>Swamy, B.</creatorcontrib><creatorcontrib>Barthelmes, D.</creatorcontrib><creatorcontrib>Day, J.O'</creatorcontrib><creatorcontrib>Cohn, A.</creatorcontrib><creatorcontrib>Fight Retinal Blindness! Study Group</creatorcontrib><title>Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project</title><title>American journal of ophthalmology</title><addtitle>Am J Ophthalmol</addtitle><description>To evaluate outcomes and predictive factors of visual acuity (VA) change after cataract surgery in patients being treated for neovascular age-related macular degeneration (nAMD).
Retrospective, matched case-control study.
We studied eyes undergoing cataract surgery that had been tracked since they first started treatment for nAMD. These eyes were compared with a cohort of unoperated phakic eyes being treated for nAMD (3 per case) matched for treatment duration before cataract surgery, baseline VA, age, and length of follow-up.
We included 124 patients that had cataract surgery and 372 matched controls. The mean (95% confidence interval) VA gained was 10.6 letters (7.8, 13.2; P < .001) 12 months after surgery; 26.0% had gained ≥3 lines and 1.6% had lost ≥3 lines of VA. Visual acuity (mean [standard deviation]) 12 months after surgery was higher in eyes that had cataract extraction compared with controls (65.8 [17.1] vs 61.3 [20.8] letters, respectively, P = .018). The proportion of visits where the choroidal neovascular (CNV) lesion was graded active and the mean number of injections were similar before and after surgery (P = .506 and P = .316, respectively), whereas both decreased in the control group, suggesting that surgery modestly increased the level of activity of the CNV lesion. Mean [SD] VA prior to surgery was lower in eyes that gained ≥15 letters compared with eyes that gained 0-14 letters (40.2 [21.4] vs 62.1 [15.1], P < .001). Patients undergoing cataract surgery within the first 6 months of anti-VEGF therapy were more likely to lose rather than gain vision (20.8% lost vision vs 12.8% and 4.4% gaining ≥15 or 0-14 letters respectively, P = .023). Age, receiving an injection at least 2 weeks before surgery, and the CNV lesion type had no discernible association with VA outcomes.
We found evidence of a modest effect of cataract surgery on CNV lesion activity in eyes being treated for nAMD. Despite this, visual outcomes were reassuringly good. Cataract surgery within 6 months of starting treatment for nAMD should be avoided if possible.</description><subject>Age</subject><subject>Aged</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Case-Control Studies</subject><subject>Cataract Extraction</subject><subject>Cataracts</subject><subject>Choroidal Neovascularization - drug therapy</subject><subject>Choroidal Neovascularization - physiopathology</subject><subject>Ethics</subject><subject>Eye surgery</subject><subject>Female</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Life Sciences</subject><subject>Macular degeneration</subject><subject>Male</subject><subject>Ophthalmology</subject><subject>Pseudophakia - physiopathology</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Visual Acuity - physiology</subject><subject>Wet Macular Degeneration - drug therapy</subject><subject>Wet Macular Degeneration - physiopathology</subject><issn>0002-9394</issn><issn>1879-1891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAUhSMEotPCA7BBRmzKIsE_ceKI1TBQijTQCopYWo59M-MoExfbGamvwtPiKKULFmxs-eo7x_fek2UvCC4IJtXbvlC9KygmosCswIQ-ylZE1E1OREMeZyuMMc0b1pQn2WkIfXpWdVk_zU5ow3lSVavs99UUtTtAQGo06NqDsTraI6ALpaPzAa27CB5tVFQ-VdD3ye_A3yE7omsVLYwxoJ827tFXcEcV9DQoj9Y7yD0MKoJBX9RS-wA7GMEnjRsLdLNPP9jdPqJvEO2oBvR-sKMZIYRXqQvXg47PsiedGgI8v7_Psh8XH282l_n26tPnzXqb65KLmGbFVQm4UrSl6eAUeFsCMAOgTAtaGIYBKBMtqcumbcE0xOCO1ZTXXacZO8veLL57Nchbbw_K30mnrLxcb-Vcw5QxzgU_ksSeL-ytd78mCFEebNAwDGoENwWZsuAlIVQ0CX39D9q7yadRZ6qkRFDSzBRZKO1dCB66hw4IlnPIspcp5NlYSMxkCjlpXt47T-0BzIPib6oJeLcAkNZ2tOBl0CkqncL1abHSOPsf-z-Db7gg</recordid><startdate>201806</startdate><enddate>201806</enddate><creator>Daien, Vincent</creator><creator>Nguyen, Vuong</creator><creator>Morlet, Nigel</creator><creator>Arnold, Jennifer J.</creator><creator>Essex, Rohan W.</creator><creator>Young, Stephanie</creator><creator>Hunyor, Alex</creator><creator>Gillies, Mark C.</creator><creator>Barthelmes, Daniel</creator><creator>Squirrel, D.</creator><creator>Field, A.</creator><creator>Dayajeewa, C.</creator><creator>Essex, R.</creator><creator>Dunlop, A.</creator><creator>Young, S.</creator><creator>Guymer, R.</creator><creator>Chow, L.</creator><creator>Amini, A.</creator><creator>Windle, P.</creator><creator>Gillies, M.</creator><creator>Chen, J.</creator><creator>Perks, M.</creator><creator>Saha, N.</creator><creator>Phillips, R.</creator><creator>Lake, S.</creator><creator>Lal, S.</creator><creator>Arnold, J.</creator><creator>Fraser-Bell, S.</creator><creator>Barnes, R.</creator><creator>Swamy, B.</creator><creator>Barthelmes, D.</creator><creator>Day, J.O'</creator><creator>Cohn, A.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><general>Elsevier Masson</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>201806</creationdate><title>Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project</title><author>Daien, Vincent ; Nguyen, Vuong ; Morlet, Nigel ; Arnold, Jennifer J. ; Essex, Rohan W. ; Young, Stephanie ; Hunyor, Alex ; Gillies, Mark C. ; Barthelmes, Daniel ; Squirrel, D. ; Field, A. ; Dayajeewa, C. ; Essex, R. ; Dunlop, A. ; Young, S. ; Guymer, R. ; Chow, L. ; Amini, A. ; Windle, P. ; Gillies, M. ; Chen, J. ; Perks, M. ; Saha, N. ; Phillips, R. ; Lake, S. ; Lal, S. ; Arnold, J. ; Fraser-Bell, S. ; Barnes, R. ; Swamy, B. ; Barthelmes, D. ; Day, J.O' ; Cohn, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-18064e06a2b26a252e5b4ee3deeadbec8d30ee238b1749bbed91d0f37257ffc33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Age</topic><topic>Aged</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Case-Control Studies</topic><topic>Cataract Extraction</topic><topic>Cataracts</topic><topic>Choroidal Neovascularization - drug therapy</topic><topic>Choroidal Neovascularization - physiopathology</topic><topic>Ethics</topic><topic>Eye surgery</topic><topic>Female</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Life Sciences</topic><topic>Macular degeneration</topic><topic>Male</topic><topic>Ophthalmology</topic><topic>Pseudophakia - physiopathology</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Visual Acuity - physiology</topic><topic>Wet Macular Degeneration - drug therapy</topic><topic>Wet Macular Degeneration - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Daien, Vincent</creatorcontrib><creatorcontrib>Nguyen, Vuong</creatorcontrib><creatorcontrib>Morlet, Nigel</creatorcontrib><creatorcontrib>Arnold, Jennifer J.</creatorcontrib><creatorcontrib>Essex, Rohan W.</creatorcontrib><creatorcontrib>Young, Stephanie</creatorcontrib><creatorcontrib>Hunyor, Alex</creatorcontrib><creatorcontrib>Gillies, Mark C.</creatorcontrib><creatorcontrib>Barthelmes, Daniel</creatorcontrib><creatorcontrib>Squirrel, D.</creatorcontrib><creatorcontrib>Field, A.</creatorcontrib><creatorcontrib>Dayajeewa, C.</creatorcontrib><creatorcontrib>Essex, R.</creatorcontrib><creatorcontrib>Dunlop, A.</creatorcontrib><creatorcontrib>Young, S.</creatorcontrib><creatorcontrib>Guymer, R.</creatorcontrib><creatorcontrib>Chow, L.</creatorcontrib><creatorcontrib>Amini, A.</creatorcontrib><creatorcontrib>Windle, P.</creatorcontrib><creatorcontrib>Gillies, M.</creatorcontrib><creatorcontrib>Chen, J.</creatorcontrib><creatorcontrib>Perks, M.</creatorcontrib><creatorcontrib>Saha, N.</creatorcontrib><creatorcontrib>Phillips, R.</creatorcontrib><creatorcontrib>Lake, S.</creatorcontrib><creatorcontrib>Lal, S.</creatorcontrib><creatorcontrib>Arnold, J.</creatorcontrib><creatorcontrib>Fraser-Bell, S.</creatorcontrib><creatorcontrib>Barnes, R.</creatorcontrib><creatorcontrib>Swamy, B.</creatorcontrib><creatorcontrib>Barthelmes, D.</creatorcontrib><creatorcontrib>Day, J.O'</creatorcontrib><creatorcontrib>Cohn, A.</creatorcontrib><creatorcontrib>Fight Retinal Blindness! Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>American journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Daien, Vincent</au><au>Nguyen, Vuong</au><au>Morlet, Nigel</au><au>Arnold, Jennifer J.</au><au>Essex, Rohan W.</au><au>Young, Stephanie</au><au>Hunyor, Alex</au><au>Gillies, Mark C.</au><au>Barthelmes, Daniel</au><au>Squirrel, D.</au><au>Field, A.</au><au>Dayajeewa, C.</au><au>Essex, R.</au><au>Dunlop, A.</au><au>Young, S.</au><au>Guymer, R.</au><au>Chow, L.</au><au>Amini, A.</au><au>Windle, P.</au><au>Gillies, M.</au><au>Chen, J.</au><au>Perks, M.</au><au>Saha, N.</au><au>Phillips, R.</au><au>Lake, S.</au><au>Lal, S.</au><au>Arnold, J.</au><au>Fraser-Bell, S.</au><au>Barnes, R.</au><au>Swamy, B.</au><au>Barthelmes, D.</au><au>Day, J.O'</au><au>Cohn, A.</au><aucorp>Fight Retinal Blindness! Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project</atitle><jtitle>American journal of ophthalmology</jtitle><addtitle>Am J Ophthalmol</addtitle><date>2018-06</date><risdate>2018</risdate><volume>190</volume><spage>50</spage><epage>57</epage><pages>50-57</pages><issn>0002-9394</issn><eissn>1879-1891</eissn><abstract>To evaluate outcomes and predictive factors of visual acuity (VA) change after cataract surgery in patients being treated for neovascular age-related macular degeneration (nAMD).
Retrospective, matched case-control study.
We studied eyes undergoing cataract surgery that had been tracked since they first started treatment for nAMD. These eyes were compared with a cohort of unoperated phakic eyes being treated for nAMD (3 per case) matched for treatment duration before cataract surgery, baseline VA, age, and length of follow-up.
We included 124 patients that had cataract surgery and 372 matched controls. The mean (95% confidence interval) VA gained was 10.6 letters (7.8, 13.2; P < .001) 12 months after surgery; 26.0% had gained ≥3 lines and 1.6% had lost ≥3 lines of VA. Visual acuity (mean [standard deviation]) 12 months after surgery was higher in eyes that had cataract extraction compared with controls (65.8 [17.1] vs 61.3 [20.8] letters, respectively, P = .018). The proportion of visits where the choroidal neovascular (CNV) lesion was graded active and the mean number of injections were similar before and after surgery (P = .506 and P = .316, respectively), whereas both decreased in the control group, suggesting that surgery modestly increased the level of activity of the CNV lesion. Mean [SD] VA prior to surgery was lower in eyes that gained ≥15 letters compared with eyes that gained 0-14 letters (40.2 [21.4] vs 62.1 [15.1], P < .001). Patients undergoing cataract surgery within the first 6 months of anti-VEGF therapy were more likely to lose rather than gain vision (20.8% lost vision vs 12.8% and 4.4% gaining ≥15 or 0-14 letters respectively, P = .023). Age, receiving an injection at least 2 weeks before surgery, and the CNV lesion type had no discernible association with VA outcomes.
We found evidence of a modest effect of cataract surgery on CNV lesion activity in eyes being treated for nAMD. Despite this, visual outcomes were reassuringly good. Cataract surgery within 6 months of starting treatment for nAMD should be avoided if possible.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29550186</pmid><doi>10.1016/j.ajo.2018.03.012</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9394 |
| ispartof | American journal of ophthalmology, 2018-06, Vol.190, p.50-57 |
| issn | 0002-9394 1879-1891 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02335585v1 |
| source | ScienceDirect Journals |
| subjects | Age Aged Angiogenesis Inhibitors - therapeutic use Case-Control Studies Cataract Extraction Cataracts Choroidal Neovascularization - drug therapy Choroidal Neovascularization - physiopathology Ethics Eye surgery Female Human health and pathology Humans Intravitreal Injections Life Sciences Macular degeneration Male Ophthalmology Pseudophakia - physiopathology Retrospective Studies Treatment Outcome Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology |
| title | Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T03%3A09%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20and%20Predictive%20Factors%20After%20Cataract%20Surgery%20in%20Patients%20With%20Neovascular%20Age-related%20Macular%20Degeneration.%20The%20Fight%20Retinal%20Blindness!%20Project&rft.jtitle=American%20journal%20of%20ophthalmology&rft.au=Daien,%20Vincent&rft.aucorp=Fight%20Retinal%20Blindness!%20Study%20Group&rft.date=2018-06&rft.volume=190&rft.spage=50&rft.epage=57&rft.pages=50-57&rft.issn=0002-9394&rft.eissn=1879-1891&rft_id=info:doi/10.1016/j.ajo.2018.03.012&rft_dat=%3Cproquest_hal_p%3E2015411289%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c458t-18064e06a2b26a252e5b4ee3deeadbec8d30ee238b1749bbed91d0f37257ffc33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2042182199&rft_id=info:pmid/29550186&rfr_iscdi=true |